

Bradford J. Duft
Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130-2081
(858) 720-2500 – Phone
(858) 720-2555 – Facsimile

This change was previously requested in Applicants' Response to the Office Action mailed August 20, 2001, in the Revocation and Grant of Power of Attorney filed on May 23, 2001, in the Revocation and Grant of Power of Attorney filed on April 10, 2001, and in the Continued Prosecution Application Request Transmittal dated February 5, 2001.

Further, please change the Attorney Docket No. from "235/013 US" to --
030639.0044.CPA1--.

Applicants request that the Examiner enter the following amendments and new claims, and consider the following remarks.

AMENDMENTS

1. A method of treating obesity in a human subject comprising administering to said subject an effective amount of an amylin or an amylin agonist.

NEW CLAIMS

Please add the following new claims 16-47:

B¹
16. (New) A method according to claim T wherein said amylin or amylin agonist is administered from 1 to 4 times per day.

17. (New) A method according to claim 1 wherein said amylin or amylin agonist is administered in an amount from about 30 µg/dose to about 300 µg/dose.

18. (New) A method according to claim 2 wherein said amylin agonist analogue is selected from the group consisting of ¹⁸Arg^{25,28,29}Pro-h-amylin and ¹⁸Arg^{25,28}Pro-h-amylin.

19. (New) A method according to claim 1 wherein said amylin or amylin agonist is administered before a meal.

20. (New) A method according to claim 19 wherein said amylin or amylin agonist is administered within about 15 minutes of said meal.

21. (New) A method according to claim 5 wherein said amylin or amylin agonist is administered before a meal.

22. (New) A method according to claim 5 wherein said amylin or amylin agonist is administered within about 15 minutes of said meal.

23. (New) A method of treating obesity in a human subject comprising administering to said subject an amount of a composition comprising an amylin or an amylin agonist effective to treat obesity, with the proviso that the composition does not contain a cholecystokinin or a cholecystokinin agonist.

24. (New) A method according to claim 23 wherein said amylin agonist is an amylin agonist analogue.

B¹cost

25. (New) A method according to claim ~~24~~ wherein said amylin agonist analogue is selected from the group consisting of ^{25,28,29}Pro-h-amylin, ¹⁸Arg^{25,28,29}Pro-h-amylin, and ¹⁸Arg^{25,28}Pro-h-amylin.

26. (New) A method according to claim ~~24~~ wherein said amylin agonist analogue is ^{25,28,29}Pro-h-amylin.

27. (New) A method according to claim ~~23~~ wherein said amylin or amylin agonist is administered subcutaneously.

28. (New) A method according to claim ~~26~~ wherein said amylin agonist analogue is administered subcutaneously.

29. (New) A method according to claim ~~23~~ wherein said amylin or amylin agonist is administered from 1 to 4 times per day in an amount from about 30 µg/dose to about 300 µg/dose.

30. (New) A method according to claim ~~23~~ wherein said amylin or amylin agonist is administered in an amount of about 0.01 milligrams per day to about 5 milligrams per day.

31. (New) A method according to claim ~~23~~ wherein said amylin or amylin agonist is administered before a meal.

32. (New) A method according to claim ~~23~~ wherein said amylin or amylin agonist is administered within about 15 minutes of said meal.

B1 cont. 33. (New) A method of treating obesity in a human subject comprising administering to said subject a composition comprising an active anti-obesity agent consisting essentially of an amylin or an amylin agonist in an amount effective to treat obesity.

34. (New) A method according to claim 33 wherein said amylin agonist is an amylin agonist analogue.

35. (New) A method according to claim 34, said amylin agonist analogue is selected from the group consisting of ^{25,28,29}Pro-h-amylin, ¹⁸Arg^{25,28,29}Pro-h-amylin, and ¹⁸Arg^{25,28}Pro-h-amylin.

36. (New) A method according to claim 34 wherein said amylin agonist analogue is ^{25,28,29}Pro-h-amylin.

37. (New) A method according to claim 33 wherein said amylin or amylin agonist is administered subcutaneously.

38. (New) A method according to claim 33 wherein said amylin or amylin agonist is administered from 1 to 4 times per day in an amount from about 30 µg/dose to about 300 µg/dose.

39. (New) A method according to claim 33 wherein said amylin or amylin agonist is administered before a meal.

40. (New) A method of treating obesity in a human subject comprising administering to said subject a composition comprising an amylin or an amylin agonist in an amount and for a duration effective to treat obesity.